Eris Lifesciences Limited Announces Postal Ballot for Appointment of Independent Director
NiveshIQ
NSE: ERIS · Healthcare
Eris Lifesciences Ltd.
₹1,160.20▲ ₹3.80 (+0.33%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ERIS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Eris Lifesciences Ltd.
Eris Lifesciences Limited, headquartered in Ahmedabad, delivers a broad portfolio of domestic branded formulations across chronic and sub‑chronic therapeutic areas such as anti‑diabetes, cardiovascular, dermatology, and oncology, and also offers patient‑care services like ambulatory blood pressure monitoring and continuous glucose monitoring. In FY27, the company generated ₹3,212 cr in revenue and ₹644 cr in net income, reflecting a robust growth trajectory driven by expanding product lines and increasing market penetration through wholesalers, retail and e‑commerce channels. Recent developments include a strategic focus on the GLP‑1 segment, where Eris is positioning itself against major pharma players in the semaglutide race, and a planned merger that could enhance scale and manufacturin
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,009 Cr +19.23% | ₹2,894 Cr +44.02% | ₹3,129 Cr +8.15% |
| EBITDA Margin | 33.59% | 35.15% | 35.79% |
| Net Profit | ₹391.98 Cr +2.57% | ₹351.84 Cr -10.24% | ₹619.52 Cr +76.08% |
| EPS | ₹28.82 | ₹25.85 | ₹45.33 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Analysts Have Been Trimming Their Eris Lifesciences Limited (NSE:ERIS) Price Target After Its Latest Report
How homegrown drugmaker Eris took on pharma giants in India’s weight loss drug race
🔒
+ 3 more stories about Eris Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹892 Cr, PAT ₹184 Cr, EPS ₹13.26, EBITDA margin 34.7%. Growth context: revenue YoY +12.6%, PAT YoY +52.9%, revenue QoQ +2.2%, PAT QoQ +29.0%.
Management commentary points to new capacity addition and capex deployment and order wins, deal pipeline, and backlog bu...
FY26 (last completed FY): revenue ₹3, 129 Cr, PAT ₹620 Cr, EBITDA margin 35.8%, EPS ₹45.33. Year-on-year: revenue YoY +8...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ERIS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ERIS alongside your other holdings
Unlock full ERIS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Eris Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Eris Lifesciences Ltd. (ERIS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Eris Lifesciences Ltd.?
Eris Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,905,731.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.